SUTRO BIOPHARMA, INC.: basic weighted-average shares

What this measure means

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Exact concept: us-gaap:WeightedAverageNumberOfSharesOutstandingBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Diluted weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

Sutro Biopharma's selected 2022 and 2023 observations come from its 2024 annual filing, which displays dollars in thousands but full shares and unscaled EPS. Potential options, restricted stock units, warrants and employee stock purchase plan shares are excluded as anti-dilutive during losses. This review preserves those historical reported values; it does not apply the later reverse split to them or approve the separate 2024 column in this older filing. Read the source filing.

Sutro Biopharma's 2025 filing presents its 2024 and 2025 share and per-share amounts after the one-for-ten reverse split, reflected in trading from December 3, 2025. It states that fractional shares were rounded up and all presented periods were adjusted retroactively. Dollar amounts are in thousands; shares and EPS are unscaled. Options, restricted stock units, warrants and employee stock purchase plan shares are excluded as anti-dilutive during losses. Earlier observations from a different filing are not automatically rescaled to this basis. Read the source filing.

Selected filing history

Related financial histories

• SUTRO BIOPHARMA, INC.: total assets
• SUTRO BIOPHARMA, INC.: total liabilities
• SUTRO BIOPHARMA, INC.: stockholders equity
• SUTRO BIOPHARMA, INC.: cash and cash equivalents
• SUTRO BIOPHARMA, INC.: net income or loss
• SUTRO BIOPHARMA, INC.: operating cash flow
• SUTRO BIOPHARMA, INC.: capital expenditure payments
• SUTRO BIOPHARMA, INC.: revenue
• SUTRO BIOPHARMA, INC.: contract revenue excluding tax
• SUTRO BIOPHARMA, INC.: financing cash flow
• SUTRO BIOPHARMA, INC.: investing cash flow
• SUTRO BIOPHARMA, INC.: retained earnings or deficit
• SUTRO BIOPHARMA, INC.: diluted weighted-average shares
• SUTRO BIOPHARMA, INC.: basic earnings per share
• SUTRO BIOPHARMA, INC.: diluted earnings per share
• SUTRO BIOPHARMA, INC.: income tax expense or benefit
• SUTRO BIOPHARMA, INC.: net property, plant and equipment
• SUTRO BIOPHARMA, INC.: share-based compensation expense
• SUTRO BIOPHARMA, INC.: operating income or loss
• SUTRO BIOPHARMA, INC.: current assets
• SUTRO BIOPHARMA, INC.: interest expense
• SUTRO BIOPHARMA, INC.: current liabilities
• SUTRO BIOPHARMA, INC.: current accounts payable
• SUTRO BIOPHARMA, INC.: net current accounts receivable
• SUTRO BIOPHARMA, INC.: operating expenses
• SUTRO BIOPHARMA, INC.: research and development expense

Inspect the source

Entity

SUTRO BIOPHARMA, INC. / CIK 0001382101

Captured

2026-09-20T07:58:19.143Z

SEC response SHA-256

edbbe5f19eb32d9e9b30b5efb21d584273fd4e0e4ee6ba6b9ca96185a3d014ff

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001382101.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))